Govt notifies NIB, Noida as CDL to test Covid-19 vaccines

The functions of the Director in respect of Covid-19 vaccines shall be exercised by the director of the NIB.

271
Govt of India
Govt of India

Last Updated on January 14, 2024 by The Health Master

The ministry of health and family welfare has notified the National Institute of Biologicals (NIB), Noida, to perform the function of the Central Drugs Laboratory (CDL) in respect of Covid-19 vaccine in order to ensure that the supply of Covid-19 vaccines is not affected.

In a notification, the department of health and family welfare said that in the backdrop of the outbreak of Covid-19 pandemic in the country and worldwide, the Central government is of the view that making suitable Covid-19 vaccines available is essential to meet the requirements of emergency arising due to the pandemic Covid-19.

Therefore, in public interest, it is necessary and expedient to regulate the testing of Covid-19 vaccine for prevention and management of Covid-19 infection.

The Central government, in consultation with the Drugs Controller General (India) (DCGI), is of the considered view that the supply of Covid-19 vaccine must not get affected and the vaccine must remain available to the public, it said.

“Now, therefore, in exercise of the powers conferred by Sections 6 and 26B read with Section 33P of the Drugs and Cosmetics Act, 1940 and Rule 3 of the Drugs Rules, 1945, the Central government, hereby directors that the National Institute of Biologicals, Noida, in addition to its existing functions shall perform the function of Central Drugs Laboratory as an additional facility in respect of Covid-19 vaccine…,” explained the notification.

The functions of the Director in respect of Covid-19 vaccines shall be exercised by the director of the NIB.

In case of any inconsistency between this notification and any rule made under the said Act, the provisions of this notification shall prevail over such rule in public interest so as to meet the requirements of emergency which have arisen due to Covid-19 pandemic, it said.

The order, which came into force on the date of publication in the Official Gazette, shall remain into force for a period of up to November 30, 2022, it added.

Commercial Testing Laboratories

Govt Laboratories

List of Laboratory instruments

NABL

Latest Notifications: Testing Laboratories

NABL 164 released : Guidelines for Inter-laboratory comparison

NABL releases NABL 136: specific criteria for X-Ray equipment

NABL: List of NABL Accredited Testing Laboratories

NABL 126: Specific criteria for calibration of Medical Devices

USFDA issues Form 483 to Alembic Pharma Gujarat plant

Pharma Manufacturing & Packaging Congress to be held in June 2022

USFDA approves generic drug for Blood Pressure

FDA Haryana and police unearthed a unit manufacturing spurious cosmetics

In-service Pharmacists authorised to dispense drugs for these 8 common ailments

Recruitment of 87 Drug Inspectors put on hold in Maharashtra

NDPS: 9 arrested for selling drugs

Drug recall: Lupin recalls 4,113 cartons of oral contraceptive

Procedure for registration of Medical Devices: CDSCO

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news